The Pulmonary and Renal and Urologic Systems

The Pulmonary and Renal and Urologic Systems

The Pulmonary and Renal and Urologic Systems 150 150 Peter

The Pulmonary and Renal and Urologic Systems

For the Pulmonary and Renal and Urologic Systems Please choose a current topic of your choosing. Some ideas you might consider are pulmonary fibrosis, impact of ESRD on other systems, asthma, etc…. you might approach it from a genetic, ethnicity, race, sex, environmental perspective. If possible, frame your topic around a nursing situation. You can build it around your practice or proposed specialty. Also you might report on two current journal articles. Please support with current scholarly references. Reply to two of your fellow students.

Sample Paper

The Pulmonary and Renal and Urologic System

Pulmonary fibrosis is a lung condition that is characterized by scarring of the lung tissues. The condition is progressive, and with time the accumulated scarring renders the lungs ineffective in facilitating gaseous exchange. The conditions are commonly idiopathic with specific identifiable causes, and their occurrence is sporadic. It can affect any individual, and most of the time, it only affects one member in a family with no history of the disease; however, in some cases, the condition can occur individuals with a history of the condition and is mostly attributed to TERC and TERT gene mutations. However, the condition is linked to exposure to environmental toxins, including coal dust, asbestos, and silica, and therefore people working in coal mining industries are at risk. Although the mechanism is unclear, chronic hypersensitivity and some medications are also linked to the disease. The most common symptoms of the disease include shortness of breath due to scarring of the lung tissues and a hacking cough that is persistent and dry (Lederer & Martinez, 2018).

The condition is most prevalent among middle-aged and older adults, with most patients being between 50 and 70 years. The idiopathic form of the disease is the most common and affects 20-30 people per 100000 worldwide; in the United States, idiopathic pulmonary fibrosis affects approximately 100 000 individuals, and up to 40000 new pulmonary fibrosis cases are made every year. The prognosis of the disease is usually poor, which explains the low number of people reported to be living with the disease. The average survival period following a diagnosis is 2 to 5 years for the patients and can be lower since, in some cases, the condition worsens within months. The death rate is estimated to be about 64.3 male deaths and 58.4 females per one million. Currently, there is no cure for this disease, and the treatment interventions such as oxygen therapy and medications are only targeted at preventing further scarring (National Institute of Health, 2022).



Lederer, D. J., & Martinez, F. J. (2018). Idiopathic pulmonary fibrosis. New England Journal of Medicine378(19), 1811-1823.

National Institute of Health, (2022) Idiopathic pulmonary fibrosis Retrieved from: